利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.02 秒)

    IL-18 and Protein Kinase R Inhibition for the Treatment of COPD
    2.
    发明申请
    IL-18 and Protein Kinase R Inhibition for the Treatment of COPD 审中-公开
    IL-18和蛋白激酶R抑制治疗COPD

    公开(公告)号：US20100247538A1

    公开(公告)日：2010-09-30

    申请号：US12601778

    申请日：2008-05-29

    申请人： Jack A. Elias ,  Chun Geun Lee ,  Min-Jong Kang

    发明人： Jack A. Elias ,  Chun Geun Lee ,  Min-Jong Kang

    IPC分类号： A61K39/395 ,  A61K31/713 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/02 ,  A61P11/00

    CPC分类号： A61K31/00 ,  G01N2333/5421 ,  G01N2333/555 ,  G01N2333/912

    摘要： The present invention encompasses compositions and methods directed to preventing, inhibiting, or treating inflammation, alveolar remodeling, or cell death in lung which results from elevation of IL-18, IFN-γ, or PKR where the methods of the present invention comprise administering an IL-18 inhibitor, an IL-18Rα inhibitor, and IFNγ inhibitor, a PKR inhibitor, and any combination thereof to an individual experiencing inflammation, alveolar remodeling, or cell death in lung. The present invention further encompasses a method of alleviating exacerbations of COPD frequently caused by viral infection by administering inflammation, alveolar remodeling, or cell death in lung to a patient with COPD at risk of developing a viral infection or who has acquired a viral infection.

    摘要翻译： 本发明包括用于预防，抑制或治疗由IL-18，IFN-γ或PKR升高引起的肺中炎症，肺泡重塑或细胞死亡的组合物和方法，其中本发明的方法包括给予 IL-18抑制剂，IL-18Rα抑制剂和IFNγ抑制剂，PKR抑制剂及其任何组合与经历肺部炎症，肺泡重塑或细胞死亡的个体。 本发明还包括通过在患有发展为病毒感染或已经获得病毒感染的风险的COPD患者中施用炎症，肺泡重塑或肺部细胞死亡而缓解由病毒感染引起的COPD加重的方法。

    Methods and Compositions Relating to CCR5 Antagonist, IFN-Gamma and IL-13 Induced Inflammation
    4.
    发明申请
    Methods and Compositions Relating to CCR5 Antagonist, IFN-Gamma and IL-13 Induced Inflammation 有权
    与CCR5拮抗剂，IFN-γ和IL-13诱导的炎症有关的方法和组合物

    公开(公告)号：US20110311560A1

    公开(公告)日：2011-12-22

    申请号：US13084239

    申请日：2011-04-11

    申请人： BING MA ,  JACK A. ELIAS

    发明人： BING MA ,  JACK A. ELIAS

    IPC分类号： A61K31/439 ,  A61P37/06 ,  A61P11/00

    CPC分类号： C07K16/2866 ,  A61K2039/505

    摘要： The present invention includes compositions and methods for the treatment of Th1 and/or Th2 mediated inflammatory diseases, relating to inhibiting CCR5. This is because the present invention demonstrates, for the first time, that expression of IFN-γ, IL-13, and CCR5, mediates and/or is associated with Th1 and/or Th2 inflammatory diseases and that inhibiting CCR5 treats, and even prevents, the diseases. Thus, the invention relates to the novel discovery that inhibiting CCR5 treats and prevents Th1 and/or Th2 mediated inflammatory disease.

    摘要翻译： 本发明包括用于治疗与抑制CCR5有关的Th1和/或Th2介导的炎性疾病的组合物和方法。 这是因为本发明首次表明IFN-γ，IL-13和CCR5的表达介导和/或与Th1和/或Th2炎性疾病相关，并且抑制CCR5治疗，甚至预防 ，疾病。 因此，本发明涉及抑制CCR5治疗和预防Th1和/或Th2介导的炎性疾病的新发现。

    Methods, compositions, and kits relating to chitinases and chitinase-like molecules and inflammatory disease
    6.
    发明申请
    Methods, compositions, and kits relating to chitinases and chitinase-like molecules and inflammatory disease 审中-公开
    与几丁质酶和几丁质酶样分子和炎性疾病有关的方法，组合物和试剂盒

    公开(公告)号：US20090148539A1

    公开(公告)日：2009-06-11

    申请号：US12218840

    申请日：2008-07-18

    申请人： Jack A. Elias ,  Zhou Zhu

    发明人： Jack A. Elias ,  Zhou Zhu

    IPC分类号： A61K33/34 ,  A61K31/7042 ,  A61K31/4353 ,  A61K33/30 ,  A61P29/00 ,  A61K33/28 ,  A61K38/12 ,  A61K31/525

    CPC分类号： A61K39/395 ,  A61K31/00 ,  A61K31/70 ,  A61K38/12 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/77 ,  C12N9/2442 ,  C12Y302/01014 ,  Y10S424/81 ,  Y10S530/868

    摘要： The present invention includes compositions and methods for the treatment of inflammatory disease (e.g. asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

    摘要翻译： 本发明包括与抑制几丁质酶样分子有关的炎性疾病（例如哮喘，COPD，炎症性肠病，特应性皮炎，特应性，过敏，过敏性鼻炎，硬皮病等）的组合物和方法。 本发明还包括鉴定用于治疗炎症性疾病的新化合物的方法，包括但不限于哮喘，COPD等。 这是因为本发明首次证明IL-13和几丁质酶样分子的表达介导和/或与炎性疾病相关，并且抑制几丁质酶样分子治疗甚至预防， 这种病。 因此，本发明涉及抑制几丁质酶样分子治疗和预防炎性疾病的新发现。

    METHODS, COMPOSITIONS, AND KITS RELATING TO CHITINASES AND CHITINASE-LIKE MOLECULES AND INFLAMMATORY DISEASE
    8.
    发明申请
    METHODS, COMPOSITIONS, AND KITS RELATING TO CHITINASES AND CHITINASE-LIKE MOLECULES AND INFLAMMATORY DISEASE 审中-公开
    方法，组合物和与基因和类似分子和炎症疾病有关的组合物

    公开(公告)号：US20090162347A1

    公开(公告)日：2009-06-25

    申请号：US12275737

    申请日：2008-11-21

    申请人： Jack A. Elias ,  Zhou Zhu

    发明人： Jack A. Elias ,  Zhou Zhu

    IPC分类号： A61K39/395 ,  A61P11/06

    CPC分类号： A61K39/395 ,  A61K31/00 ,  A61K31/70 ,  A61K38/12 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/77 ,  C12N9/2442 ,  C12Y302/01014 ,  Y10S424/81 ,  Y10S530/868

    摘要： The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

    摘要翻译： 本发明包括与抑制几丁质酶样分子有关的炎性疾病（例如哮喘，COPD，炎性肠病，特应性皮炎，特应性，过敏，过敏性鼻炎，硬皮病等）的组合物和方法。 本发明还包括鉴定用于治疗炎症性疾病的新化合物的方法，包括但不限于哮喘，COPD等。 这是因为本发明首次证明IL-13和几丁质酶样分子的表达介导和/或与炎性疾病相关，并且抑制几丁质酶样分子治疗甚至预防， 这种病。 因此，本发明涉及抑制几丁质酶样分子治疗和预防炎性疾病的新发现。

    Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
    9.
    发明申请
    Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases 审中-公开
    与血管内皮生长因子和TH2介导的炎症疾病有关的方法和组成

    公开(公告)号：US20090155266A1

    公开(公告)日：2009-06-18

    申请号：US10586254

    申请日：2005-01-18

    申请人： Jack A. Elias

    发明人： Jack A. Elias

    IPC分类号： A61K39/395 ,  A61K31/7052 ,  A61K38/02 ,  A61P29/00 ,  A61K38/43 ,  G01N33/68

    CPC分类号： A61K31/712 ,  C07K16/22 ,  G01N33/74 ,  G01N2333/71 ,  G01N2800/122

    摘要： The present invention includes compositions and methods for the treatment of a Th2 mediated inflammatory disease, relating to inhibiting a VEGF. The invention further includes methods to identify new compounds for the treatment of a Th2 mediated inflammatory disease, including, but not limited to, asthma and the like. This is because the present invention demonstrates, for the first time, that expression of VEGF induces asthma-like phenotype and that inhibiting VEGF reverses the phenotype. Thus, the invention relates to the novel discovery that inhibiting VEGF treats and prevents an Th2 mediated inflammatory disease.

    摘要翻译： 本发明包括用于治疗与抑制VEGF有关的Th2介导的炎性疾病的组合物和方法。 本发明还包括鉴定用于治疗Th2介导的炎性疾病的新化合物的方法，包括但不限于哮喘等。 这是因为本发明首次证明VEGF的表达诱导哮喘样表型，并且抑制VEGF逆转表型。 因此，本发明涉及抑制VEGF治疗和预防Th2介导的炎性疾病的新发现。